EASD 2013:6个生物标志物与2型糖尿病CVD的预测相关

2013-10-12 佚名 丁香园

第49届欧洲糖尿病研究协会(EASD2013)于9月23-27日在西班牙巴塞罗那召开。当地时间9月24日上午,在“Predictors of cardiovascular disease”专场上,英国邓迪大学Helen C Looker博士报道的一项研究证实,有6个生物标志物与2型糖尿病患者心血管疾病(CVD)的预测相关。 Looker博士在报告中说,“我们报告了我们认为的一个新发现,即白细胞介

第49届欧洲糖尿病研究协会(EASD2013)于9月23-27日在西班牙巴塞罗那召开。当地时间9月24日上午,在“Predictors of cardiovascular disease”专场上,英国邓迪大学Helen C Looker博士报道的一项研究证实,有6个生物标志物与2型糖尿病患者心血管疾病(CVD)的预测相关。

Looker博士在报告中说,“我们报告了我们认为的一个新发现,即白细胞介素-15可预测2型糖尿病CVD事件。此外,载脂蛋白C-III 和可溶性RAGE (sRAGE)与CVD事件也有关联,这个结果是出乎意料的,值得进一步去探讨。”

根据研究摘要,这项研究纳入了Go-DARTS(n=1,204)、斯堪尼亚糖尿病注册表组(n =666)、MONICA/KORA组(n=308)、IMPROVE (n=94)和 60岁斯德哥尔摩研究组(n=64)的2型糖尿病患者。

Looker博士和同事们检测了42个生物标志物,但只有16个标志物可进一步改善对心血管疾病的预测。

Looker博士说:“我们所测试的生物标志物许多与CVD事件有关,但在选择时,我们发现除了临床协变量,主要是6个标志物对预测有改善。”

与心血管疾病具有最显著关联的是:

N -末端前B型利钠肽( OR = 1.72 ,95%CI,1.49-1.99 );

载脂蛋白C-III (OR = 1.26 ,95% CI , 1.10-1 .43);

sRAGE(OR = 0.82,95% CI, 0.73-0.91);

高敏肌钙蛋白T(OR = 0.85,95% CI, 0.77-0.94 );

IL -6 (OR = 1.16,95% CI, 1.05-1.29 );

IL -15 ( OR = 1.17,95% CI, 1.06-1.29 )。

“我们认为这些研究结果已经有力,因为多个研究都有发现,但我们还需要在其它队列中进行重复,这也是我们正在做的,”Looker博士说。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1690573, encodeId=f02e16905e37e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun May 04 06:35:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840779, encodeId=60991840e79c6, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jan 09 14:35:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534067, encodeId=fff5153406e2a, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560508, encodeId=461415605088a, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566517, encodeId=5423156651ec7, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
    2014-05-04 okhuali
  2. [GetPortalCommentsPageByObjectIdResponse(id=1690573, encodeId=f02e16905e37e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun May 04 06:35:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840779, encodeId=60991840e79c6, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jan 09 14:35:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534067, encodeId=fff5153406e2a, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560508, encodeId=461415605088a, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566517, encodeId=5423156651ec7, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1690573, encodeId=f02e16905e37e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun May 04 06:35:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840779, encodeId=60991840e79c6, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jan 09 14:35:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534067, encodeId=fff5153406e2a, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560508, encodeId=461415605088a, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566517, encodeId=5423156651ec7, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
    2013-10-14 qilu_qi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1690573, encodeId=f02e16905e37e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun May 04 06:35:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840779, encodeId=60991840e79c6, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jan 09 14:35:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534067, encodeId=fff5153406e2a, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560508, encodeId=461415605088a, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566517, encodeId=5423156651ec7, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1690573, encodeId=f02e16905e37e, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sun May 04 06:35:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840779, encodeId=60991840e79c6, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jan 09 14:35:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534067, encodeId=fff5153406e2a, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560508, encodeId=461415605088a, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566517, encodeId=5423156651ec7, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Mon Oct 14 07:35:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]

相关资讯

肥胖和2型糖尿病热点问题

肥胖和糖尿病 2型糖尿病(T2DM)患者中有80%~90%超重或肥胖。我国现有超重和肥胖者共2.8亿人,其中超重者2.1亿人,肥胖者6844万人,这表明,我国人群不再是低体质指数(BMI)的瘦小人群,肥胖高发病率无疑又会为糖尿病、高血压、高血脂等慢性病发病埋下沉重的伏笔。 T2DM是肥胖时风险最大的健康隐患。肥胖及其伴随的胰岛素抵抗是T2DM发病的关键因素。一项荟萃分析表明,不论在男性还是女性

EASD 2013:高甘油三酯血症与2型糖尿病患者并发症的关系

在9月23日至27日召开的欧洲糖尿病研究学会(EASD)第49届年会上,一项意大利的多中心研究报告指出,高甘油三酯(HTG)与所有的CKD 表型有联系、不依赖他汀类药治疗,而后者与心血管疾病(CVD)有联系、不依赖甘油三酯(TG)水平。这些数据指出HTG在慢性肾病(CKD)发生中可能的作用,和治疗致动脉粥样硬化的血脂异常的重要性。 致动脉粥样硬化的血脂异常,即高甘油三

EASD 2013:2型糖尿病患者一日少次多量进餐或能获益更多

2型糖尿病(T2D)治疗中热量限制是非常重要,典型的方法是(但也不一定)将一天中总热量分为5或6次少量进餐。已有证据表明等热量的大量混合餐比相同食物分为6小份消耗导致更多的餐后产热效应。为了比较2型糖尿病患者在相同热量限制下,一天6次进餐与一天两次进餐对体重、HbA1c和静息能量消耗的影响,来自捷克布拉格内分泌研究所的Hana Kahleova教授及其团队进行了一项研究,该研究发现2型糖尿病患

赛诺菲Lyxumia联合基础胰岛素显著改善血糖控制

赛诺菲(Sanofi)9月25日公布了GetGoal-L研究的亚组分析结果。数据表明,在基线空腹血糖(FPG)良好控制的2型糖尿病患者中,将Lyxumia(lixisenatide)添加至基础胰岛素时,糖化血红蛋白(HbA1c)水平取得了最大幅度的降低,并使这组患者的体重水平也得到了最大幅度的下降。这些发现与Lyxumia的疗效档案一致,表明Lyxumia在不同患者群体中,均能实现临床显著

国内研究;住院2型糖尿病并原发性青光眼患者多为闭角型青光眼

福建医科大学附属第二医院内分泌科周竟雄、施亚雄和林家煜等探讨了2型糖尿病患者发生原发性青光眼的危险因素。结果表明,住院2型糖尿病并原发性青光眼患者多为闭角型青光眼,致盲率高;老年、女性、高收缩压、代谢综合征可能是糖尿病并原发性青光眼的危险因素。 相关论文发表于2013年第8期《中华内分泌代谢杂志》 。 研究者们选取住院患者167例,2型糖尿病并原发性青光眼组61例;2型糖尿病

EC批准武田3种糖尿病新药

武田(Takeda)9月24日宣布,3种2型糖尿病新药:二肽基肽酶IV(DPP-4)抑制剂Vipidia(alogliptin)、固定剂量组合Vipdomet(alogliptin+二甲双胍)、Incresync(alogliptin+吡格列酮)均获得了欧盟委员会(EC)批准,用于现有疗法无法控制其血糖水平的2型糖尿病患者。【原文阅读】 这3种新药的获批,是基于一项强有力的临床试验项目的数据